posted on 2015-04-24, 16:10authored bySamantha Johnson, T. Alun Evans, Elizabeth S. Draper, David J. Field, Bradley N. Manktelow, N. Marlow, Ruth Matthews, S. Petrou, Sarah E. Seaton, Lucy K. Smith, Elaine M. Boyle
Objective. There is a paucity of data relating to neurodevelopmental outcomes in infants born late
and moderately preterm (LMPT; 32[SUPERSCRIPT +0]-36[SUPERSCRIPT +6] weeks). This paper present results of a prospective,
population-based study of 2-year outcomes following LMPT birth.
Design.1130 LMPT and 1255 term-born children were recruited at birth. At 2-years corrected age,
parents completed a questionnaire to assess neurosensory (vision, hearing, motor) impairments and
the Parent Report of Children’s Abilities-Revised to identify cognitive impairment. Relative Risks for
adverse outcomes were adjusted for sex, socio-economic status, small for gestational age and
weighted to account for over-sampling of term-born multiples. Risk factors for cognitive impairment
were explored using multivariable analyses.
Results. Parents of 638 (57%) LMPT infants and 765 (62%) controls completed questionnaires.
Among LMPT infants, 1.6% had neurosensory impairment compared with 0.3% of controls (RR 4.89,
95% CI 1.07, 22.25). Cognitive impairments were the most common adverse outcome: LMPT 6.3%;
controls 2.4% (RR 2.09, 95% CI 1.19, 3.64). LMPT infants were at twice the risk for
neurodevelopmental disability (RR 2.19, 95% CI 1.27, 3.75). Independent risk factors for cognitive
impairment in LMPT infants were male sex, socio-economic disadvantage, non-white ethnicity,
preeclampsia and not receiving breast milk at discharge.
Conclusions. Compared with term-born peers, LMPT infants are at double the risk for
neurodevelopmental disability at 2 years of age, with the majority of impairments observed in the
cognitive domain. Male sex, socio-economic disadvantage and preeclampsia are independent
predictors of low cognitive scores following LMPT birth.
Funding
National Institute for Health Research (NIHR) under its Programme Grants for Applied Research (PGfAR) Programme
(Grant Reference Number RP-PG-0407-10029). Neil Marlow receives a
proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding
scheme at UCLH/UCL.
History
Citation
Archives of Disease in Childhood Fetal Neonatal Edition 2015;0:F1–F8
Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Health Sciences
Version
VoR (Version of Record)
Published in
Archives of Disease in Childhood Fetal Neonatal Edition 2015;0:F1–F8
Publisher
BMJ Publishing Group for Royal College of Paediatrics and Child Health, European Academy of Paediatrics